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Move through  
the Light
Although allogeneic 
hematopoietic cell 
transplantation (allo-HCT) 
is potentially lifesaving 
for leukemia, lymphoma, 
and myeloma patients, 
development of graft-versus-
host disease (GvHD) following 
transplantation is a dangerous 
possibility. Kreutz and colleagues 
demonstrated that whole-body 
broadband UVB irradiation at 
the time of allo-HCT is safe, and 
that the resultant Langerhans 
cell depletion was associated 
with decreased acute GvHD 
in these transplantation 
patients. In particular, UVB 
exposure led to increased 
levels of immunosuppressive 
25-hydroxyvitamin D3 
and increased circulating T 
regulatory cells. Future studies 
will assess the clinical benefits of 
prophylactic UVB exposure with 
allo-HCT to prevent GvHD.  
See page 179
More Filaggrin, Please
Increased risk of atopic 
dermatitis (AD) is associated 
with null mutations in the 
filaggrin gene (FLG), which also 
exhibits copy number variation 
(CNV) at the DNA level. Brown 
and colleagues employed PCR-
based genotyping strategies 
to determine whether CNV 
within the FLG gene affected 
AD risk in a case–control study 
of 925 pediatric AD cases and 
998 controls. A significantly 
higher copy number was found 
in the controls than in the AD 
cases, indicating that CNV 
within FLG affects AD risk in a 
dose-dependent manner and 
that therapeutically increasing 
filaggrin expression may be 
beneficial in AD. See page 98
Topical Immune Boost
Immune-stimulating agents 
have been suggested to 
provide immunoprotective 
benefits to melanoma 
patients when used prior 
to surgical tumor removal. 
To examine the effects of 
imiquimod, the synthetic Toll-like receptor 7 agonist typically used in such a situation 
for topical treatment of genital warts, superficial basal cell carcinoma, and actinic 
keratosis, Narayan and colleagues conducted a pilot study of 14 individuals who had 
primary melanoma tumors with a Breslow thickness >1.0 mm. Topical imiquimod 
treatment elevated levels of CD4+ and CD8+ lymphocytes in the skin and in the drain-
ing lymph nodes compared with placebo treatment, supporting additional clinical 
investigation into the use of this therapy for melanoma. See page 163
Risky Blisters
A higher risk of death among 
pemphigus patients was previ-
ously reported in a hospital-
based study. Huang and col-
leagues investigated mortality 
from pemphigus in a large repre-
sentative cohort of 853 patients 
from Taiwan and compared these 
data with those for the general 
population. This study revealed 
a pemphigus incidence of 4.7 
cases per million per year in 
Taiwan. Furthermore, survival in 
patients diagnosed with pemphi-
gus was significantly lower than in the general population, with an overall 2.36-fold 
higher mortality for the pemphigus patients. Interestingly, these patients have a higher 
risk of mortality from systemic and respiratory tract infections, cardiovascular dis-
ease, and peptic ulcer disease compared with the general population. See page 92
Baby on Board
Inflammation, such as that experienced with pso-
riasis, can be associated with adverse pregnancy 
outcomes such as preterm birth (PTB) and low 
birth weight (LBW). Lima and colleagues found 
that women with psoriasis had an increased risk of 
both PTB and LBW as compared with non-psoriasis 
patients in a retrospective cohort study. These results 
emphasize the necessity of control of psoriasis 
before conception and during pregnancy. This goal 
is a real possibility now that new treatment options 
are available and their safety in pregnancy is being 
evaluated. See page 85
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